Exicure, Inc.

Exicure, Inc.

Exicure, Inc. was incorporated as a biotechnology firm that sought to exploit spherical nucleic acid (SNA) technology, a platform distinct from traditional linear nucleic acid delivery. Founders included scientists from Northwestern University. The company went public via a SPAC merger in 2021, raising capital to advance its pipeline of SNA-based therapies. Exicure's strategy revolved around internal discovery and development, covering candidates in genetic disorders and inflammatory diseases. Its platform, known as SNA technology, aimed to deliver oligonucleotides without viral vectors. The firm disclosed a pipeline including XCUR-17 for psoriasis and atopic dermatitis, as well as preclinical programs for Huntington's disease. Geographic footprint was US-based, with research operations in the Chicago area. By 2023, Exicure faced significant financial challenges, including layoffs and a restructuring. The firm's workforce shrunk to under 10 employees by late 2022. No additional offices or philanthropic vehicles were publicly reported. The company's last major operational event was a notification of non-compliance with Nasdaq listing requirements in 2022. Structurally, Exicure's differentiator was its focus on SNA — a delivery technology that allows precise arrangement of nucleic acids on a nanoparticle core. This architecture differentiated it from other oligonucleotide firms, offering potential advantages in cellular uptake and tissue targeting. However, the company struggled to advance candidates to later-stage clinical trials or secure partnership revenue.